晚期胰腺癌:治疗标准和新机遇。

IF 3.1 Q2 ONCOLOGY

Oncology Reviews Pub Date : 2018-09-14 eCollection Date: 2018-07-04 DOI:10.4081/oncol.2018.370

Amrallah A Mohammad

{"title":"晚期胰腺癌:治疗标准和新机遇。","authors":"Amrallah A Mohammad","doi":"10.4081/oncol.2018.370","DOIUrl":null,"url":null,"abstract":"Presentation of pancreatic cancer is localized, locally advanced or metastatic. With the later represented the main bulk (more than 80%). Despite the significant innovation in molecular analysis and therapeutic approach in many types of cancer in the last two decades, still the outcome of advanced pancreatic cancer is disappointing and the mortality rate approximately unchanged. In this mandated review we intended to highlight the standard of care and emerging agents for advanced pancreatic cancer treatment.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"12 2","pages":"370"},"PeriodicalIF":3.1000,"publicationDate":"2018-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2018.370","citationCount":"10","resultStr":"{\"title\":\"Advanced pancreatic cancer: The standard of care and new opportunities.\",\"authors\":\"Amrallah A Mohammad\",\"doi\":\"10.4081/oncol.2018.370\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Presentation of pancreatic cancer is localized, locally advanced or metastatic. With the later represented the main bulk (more than 80%). Despite the significant innovation in molecular analysis and therapeutic approach in many types of cancer in the last two decades, still the outcome of advanced pancreatic cancer is disappointing and the mortality rate approximately unchanged. In this mandated review we intended to highlight the standard of care and emerging agents for advanced pancreatic cancer treatment.\",\"PeriodicalId\":19487,\"journal\":{\"name\":\"Oncology Reviews\",\"volume\":\"12 2\",\"pages\":\"370\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2018-09-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.4081/oncol.2018.370\",\"citationCount\":\"10\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncology Reviews\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4081/oncol.2018.370\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2018/7/4 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/oncol.2018.370","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/7/4 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 10

摘要

胰腺癌的表现为局部、局部晚期或转移性。以后者为主体(占80%以上)。尽管在过去的二十年中，许多类型的癌症在分子分析和治疗方法上有了重大的创新，但晚期胰腺癌的结果仍然令人失望，死亡率几乎没有变化。在这篇强制性的综述中，我们旨在强调晚期胰腺癌治疗的护理标准和新兴药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Advanced pancreatic cancer: The standard of care and new opportunities.

查看原文本刊更多论文

Advanced pancreatic cancer: The standard of care and new opportunities.

Presentation of pancreatic cancer is localized, locally advanced or metastatic. With the later represented the main bulk (more than 80%). Despite the significant innovation in molecular analysis and therapeutic approach in many types of cancer in the last two decades, still the outcome of advanced pancreatic cancer is disappointing and the mortality rate approximately unchanged. In this mandated review we intended to highlight the standard of care and emerging agents for advanced pancreatic cancer treatment.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Oncology Reviews ONCOLOGY-

CiteScore

6.30

自引率

0.00%

发文量

审稿时长

9 weeks

期刊介绍： Oncology Reviews is a quarterly peer-reviewed, international journal that publishes authoritative state-of-the-art reviews on preclinical and clinical aspects of oncology. The journal will provide up-to-date information on the latest achievements in different fields of oncology for both practising clinicians and basic researchers. Oncology Reviews aims at being international in scope and readership, as reflected also by its Editorial Board, gathering the world leading experts in both pre-clinical research and everyday clinical practice. The journal is open for publication of supplements, monothematic issues and for publishing abstracts of scientific meetings; conditions can be obtained from the Editor-in-Chief or the publisher.